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Abstract
OBJECTIVE—To investigate the relationship between a panel of angiogenic and inflammatory 
biomarkers measured in mid-pregnancy and small-for-gestational age (SGA) outcomes in sub-
Saharan Africa.
STUDY DESIGN—Concentrations of 18 angiogenic and inflammatory biomarkers were 
determined in 432 pregnant women in Dar es Salaam, Tanzania who participated in a trial 
examining the effect of multivitamins on pregnancy outcomes. Infants falling below the 10th 
percentile of birth weight for gestational age relative to the applied growth standards were 
considered SGA. Multivariate binomial regression models with the log link function were used to 
determine the relative risk of SGA associated with increasing quartiles of each biomarker. 
Stepwise cubic restricted splines were used to test for non-linearity of these associations. Receiver 
operating curves obtained from multivariate logistic regression models were used to assess the 
discriminatory capability of selected biomarkers.
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RESULTS—A total of 60 participants (13.9%) gave birth to SGA infants. Compared to those in 
the first quartile, the risk of SGA was reduced among those in the fourth quartiles of VEGF-A 
(adjusted risk ratio (RR) 0.38, 95% Confidence Interval (CI), 0.19-0.74), PGF (adjusted RR 0.28, 
95% CI, 0.12-0.61), sFlt-1 (adjusted RR 0.48, 95% CI, 0.23-1.01), MCP-1 (adjusted RR 0.48, 
95% CI, 0.25-0.92), and Leptin (adjusted RR 0.46, 95% CI, 0.22-0.96)
CONCLUSION—Our findings provide evidence of altered angiogenic and inflammatory 
mediators, at mid-pregnancy, in women who went on to deliver small for gestational age infants.
Keywords
Angiogenesis; inflammation; small-for-gestational age
INTRODUCTION
Intrauterine growth restriction (IUGR) is a major public health problem that affects 4-8% of 
pregnancies in developed countries1 and an estimated 27% of pregnancies in low and middle 
income countries.2 The consequences of inadequate fetal growth can be life-long. Growth-
restricted infants have an increased risk of morbidity and mortality during the neonatal and 
post-neonatal period, an increased risk of developmental delay, short stature, 
neurodevelopmental impairment and cerebral palsy during childhood as well as an increased 
risk of myriad cardiometabolic disorders during adulthood.1,2, 3
A small number of interventions have had modest success in reducing the occurrence of 
smallness for gestational age (SGA)4, a commonly used surrogate outcome for IUGR. 
Nonetheless, considerable demand still exists for effective preventive measures. 
Development of these measures requires an improved understanding of the pathogenesis of 
IUGR and the ability to identify pregnancies at risk in early and mid-gestation. The 
examination of biomarkers associated with reduced fetal growth can assist in both 
endeavors.
Previous studies have linked a number of biomarkers to IUGR5 but few have been 
conducted in resource-constrained settings where the burden of IUGR is greatest. Much of 
this research has focused on biomarkers of angiogenesis, the branching and non-branching 
remodelling of the placental vasculature6 that is a crucial process for adequate perfusion of 
oxygen and nutrients to the fetus. Other evidence suggests that IUGR may involve a 
proinflammatory cytokine bias.7. For this reason, evaluating the association between 
inflammatory biomarkers and IUGR may be of particular relevance in developing countries, 
where common infections such as malaria can induce a proinflammatory microenvironment. 
In this study, we investigate the relationship between a range of angiogenic and 
inflammatory biomarkers during mid-pregnancy and intrauterine growth restriction as 
defined by SGA.
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MATERIALS AND METHODS
Study site and participants
We obtained data and specimens for these analyses from a randomized, double-blind, 
placebo-controlled trial of daily multivitamin supplementation during pregnancy. A detailed 
description of the trial has been published elsewhere.8 Trial participants were HIV-negative, 
between 12 and 27 weeks of gestation, and planning to stay in Dar es Salaam for at least 1 
year after delivery. At the time of enrollment, participants were randomly assigned to 
receive a daily oral dose of a multivitamin containing 20 mg of vitamin B1, 20 mg of 
vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin 
C, and 20 mg of vitamin E, or a placebo. All trial participants also received daily doses of 60 
mg of elemental iron and 0.25 mg of folic acid. We limited the present analyses to 
primigravid women, since they are at higher risk for fetal growth restriction than multigravid 
women.9 In addition, we limited these analyses to singleton births. Multiple gestations are 
associated with both alterations in angiogenic markers10 and a higher risk of adverse 
pregnancy outcomes11 and could therefore confound the results of the study. From among 
the subset of primigravid trial participants with singleton pregnancies, known birth 
outcomes, and stored baseline plasma samples, we randomly selected 432 participants for 
these analyses.
Ethics Statement
The Institutional Review Boards at the Muhimbili University of Health and Allied Sciences 
in Dar es Salaam and the Harvard School of Public Health in Boston granted ethical 
approval for the study.
Exposure
Maternal peripheral blood samples were collected in EDTA vacutainer tubes at enrolment, 
plasma separated, and stored at −80°C prior to testing. For the present study, plasma 
samples underwent analysis for the following 18 angiogenic and inflammatory biomarkers: 
angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), angiopoietin-like 3 (Angptl3), vascular 
endothelial growth factor (VEGF-A), soluble fms-like tyrosine kinase 1 (sFlt-1), soluble 
tumor necrosis factor receptor 2 (sTNFR2), placental growth factor (PGF), macrophage 
inflammatory protein-1 beta (MIPβ/CCL4), monocyte chemoattractant protein-1 (MCP-1/
CCL2), Leptin, interleukin-1 beta (IL1β), interleukin-18 binding protein (IL-18BP), soluble 
intercellular adhesion molecule-1 (sICAM1), Complement Factor D (Factor D), soluble 
endoglin (sEng), C-reactive protein (CRP), chitinase-3-like protein-1 (CHI3L1), and 
complement component C5a (C5a). All analyses utilized commercially available ELISAs 
(Duosets, R&D Systems, Minneapolis, MN). To increase sensitivity, samples were 
incubated for two hours at room temperature (18-28°C) for the analyses of CRP, C5a, Factor 
D and VEGF-A, and overnight at 4°C for the analyses of all other biomarkers. ELISA 
analysis was blinded to infant size for gestational age at birth.
DARLING et al. Page 3
Am J Obstet Gynecol. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Outcomes
At enrollment, participants reported the date of their last menstrual period (LMP). These 
dates were used to calculate gestational ages. Research midwives measured birth weights of 
newborns to the nearest 10 g following delivery. We defined SGA births as those falling 
below the 10th percentile of birth weight for gestational age as in the parent study.8
Statistical analysis
We tested the distributions of each biomarker for normality using the Shapiro-Wilks test. 
Because the distributions of each biomarker deviated from normality, we used the Wilcoxon 
rank-sum test to non-parametrically examine whether the levels of each biomarker differed 
between SGA and appropriate-for-gestational age (AGA) infants. We estimated the relative 
association between each biomarker and SGA by categorizing each participant's biomarker 
values into quartiles and using log-binomial regression to determine the risk ratios and 95% 
confidence intervals for SGA for participants in each of the upper 3 quartiles compared to 
those in the lowest quartile. In most cases, the log-binomial models failed to converge and 
were replaced with log-Poisson models, which provide consistent but not fully efficient 
estimates of the risk ratio and its confidence intervals.13 Multivariate models also contained 
terms for covariates that predicted SGA at an alpha level of less than 0.2 in univariate log-
binomial models. These variables included literacy (yes/no), marital status (yes/no), 
gestational age at study entry (<20, 20-25, 25-30 weeks), and district of recruitment (Ilala/
Temeke/Kinondoni). We non-parametrically examined the possibility of non-linear 
relationships between continuous biomarker levels and SGA status using restricted cubic 
splines14 with four knots placed at the points corresponding to the 20th, 40th, 60th, and 80th 
percentiles. For biomarkers that did not depart from linearity in relation to SGA status, we 
then tested for the presence of linear trends by assigning each quartile the median value and 
modeling this variable as a continuous variable.
Because multivitamin supplementation reduced the risk of SGA in the parent trial,8 we 
considered assigned treatment arm in the parent trial as a potential modifier of the 
relationship between each biomarker and the risk of an SGA birth. To do so, we 
dichotomized each biomarker at the median to create “high” and “low” categories, computed 
cross product terms by multiplying the dichotomous biomarker variables by the indicator 
variable for treatment arm, and assessed the significance of this cross-product term using a 
likelihood ratio test. All statistical analyses were performed using SAS 9.2 software (SAS 
Institute, Cary, NC).
RESULTS
Participant characteristics are presented in Table 1. At the time of enrollment into the parent 
trial, participants had a median age of 20.6 (IQR 18.6-22.6) and a median gestational age of 
22 weeks (IQR 19.4 – 24.6). The majority of participants (67.4%) were of normal weight for 
height. Eleven percent of participants had a mid-upper arm circumference of 22.5 cm or less. 
Approximately one fifth of participants reported that their household spent 500 Tanzanian 
shillings or less (US $0.31) per person per day on food. The majority of participants were 
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able to read (90.5%), had completed less than 8 years of schooling (73.8%), and were 
married (79.2%). Of the 432 participants, 60 (13.9%) delivered infants that were SGA.
Table 2 displays the median values of each biomarker among SGA and AGA deliveries. 
Compared to women who gave birth to AGA infants, women who gave birth to SGA infants 
had notably lower median levels of VEGF-A (9.43 pg/ml (interquartile range (IQR) 7.81, 
85.38) vs. 51.08 pg/ml (IQR 7.81, 363.54)), sFlt-1 (0.94 ng/ml (IQR 0.23, 2.38) vs. 1.31 
ng/ml (IQR 0.55, 4.11)), PGF (1.18 ng/ml (IQR 0.65, 1.98) vs. 1.61 ng/ml (IQR 0.91, 2.84)), 
MCP-1/CCL2 (20.91 pg/ml (IQR 7.81, 187.09) vs. 48.14 pg/ml (11.56, 247.91)), and Leptin 
(7.74 ng/ml (IQR 4.76, 12.88) vs. 6.36 (IQR 4.04, 10.42)), and notably higher levels of 
sICAM-1 (184.53 ng/ml (IQR 120.93, 241.80) vs. 157.68 ng/ml (95% CI 109.40, 237.01)).
Since the biomarkers examined have unique profiles with respect to gestational age, we 
examined biomarker levels according to the gestational age at which the plasma sample was 
collected. Median levels of VEGF-A and sFlt-1 were consistently lower in the SGA group 
compared to the AGA group among women who were between 12-16 weeks of gestation, 
17-21 weeks of gestation, and 22-27 weeks of gestation (Figure 1a,b). Median levels of PGF 
and MCP-1/CCL2 were higher in the SGA group compared to the AGA group among 
women who were between 12-16 weeks of gestation, but lower among women who were 
between 17-21 weeks of gestation and 22-27 weeks of gestation (Figure 1c,d). The lower 
median levels of Leptin in the SGA group were only apparent among women who were 
22-27 weeks of gestation, and the higher median levels of sICAM-1 were observed only 
among women who were 17-21 weeks of gestation (Figure 1e,f).
Table 3 shows the relative risks for an SGA delivery according to quartiles of biomarker 
values. Women with VEGF-A levels in the third and fourth quartiles had a significantly 
reduced risk of giving birth to an SGA infant compared to women in the first quartile, but 
this reduction was more pronounced in the third quartile (multivariate risk ratio 0.24; 95% 
CI (0.11, 0.53)) than in the fourth quartile (multivariate risk ratio 0.38; (95% CI 0.19, 0.74)). 
Spline analysis confirmed a significant non-linear relationship (p=0.001) between VEGF-A 
and SGA status that appeared L-shaped, with a relatively constant reduction in the odds of 
SGA observed at concentrations of approximately 100 pg/ml and above (Figure 2). Women 
with plasma PGF in the highest quartile had a statistically significant reduced risk of 
delivering an SGA infant (72%; 95% CI 59%, 88%) compared to those in the lowest 
quartile. Similar to the results for VEGF-A, spline analysis showed that PGF had a 
significant non-linear relationship to SGA (p=0.008) that showed an L-shape (Figure 3). At 
PGF concentrations of approximately 4 ng/ml and above, the reduction in odds associated 
with each increasing ng/ml of PGF seemed to remain relatively constant.
We also observed associations between Leptin, sFlt-1, MCP-1/CCL2, and sICAM-1 and 
SGA status. Compared to women in the first quartile, women with plasma Leptin in the 
fourth quartile had a 54% (95% CI 4%, 78%) reduced risk of SGA. sFlt-1 in the highest 
quartile was associate with a reduced risk of delivering an SGA infant that approached 
statistical significance (multivariate risk ratio 0.48; 95% CI 0.23, 1.01). Across increasing 
quartiles of MCP-1/CCL2, the risk of SGA decreased by 56% (95% CI 13%, 77%), 47% 
(95% CI 2%, 71%), and 52% (95% CI 8%, 75%) respectively. Though the relative risks for 
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the upper quartiles of sICAM-1 were not associated with SGA risk, spline analysis 
suggested a non-linear relationship between sICAM-1 and SGA (p=0.02). Treatment 
assignment in the parent trial did not significantly modify the associations between any of 
the other biomarkers and SGA.
COMMENT
We found that higher plasma levels of the pro-angiogenic markers VEGF-A, PGF, and the 
anti-angiogenic marker sFlt-1 at mid-pregnancy were associated with a reduced risk of 
giving birth to an SGA infant. The L-shape of these associations implies that reaching 
critical thresholds of these proteins may be necessary for adequate fetal growth. Based on 
our data, these thresholds appear to exist around 100 pg/ml for VEGF-A and 4 ng/ml for 
PGF. In addition, higher levels of the inflammatory protein, MCP-1 and the adipocytokine 
hormone, Leptin were also associated with a reduced risk of delivering an SGA infant.
VEGF-A, PGF, and s-Flt all belong to the vascular endothelial growth factor (VEGF) family 
of structurally similar proteins which are essential for placental vascular development. 
VEGF-A is necessary for vasculogenesis,6 the formation of the blood vessels from a 
previously avascular area, which occurs primarily in the first trimester. In the second and 
third trimester, both VEGFA and PGF regulate angiogenesis, the elongation, branching and 
vascular remodelling critical to support rapid fetal growth in late pregnancy.15 Our findings 
suggest that dysregulated levels of pro-and anti-angiogenic factors at mid-pregnancy are 
associated with SGA outcomes. There results add to a growing body of evidence implicating 
altered levels of VEGF-A, PGF and s-Flt-1 in placental insufficiency and fetal growth 
restriction.16-23
sFlt-1 is an alternatively spliced variant of VEGFR1 that has an inhibitory effect on VEGF-
A and PGF signalling.24 During pregnancy, trophoblast cells secrete large amounts of 
soluble receptors that modulate the levels of bioavailable VEGF-A and PGF.25 In this study 
higher levels of levels of sFlt-1 were associated with a reduced risk of risk of SGA, in 
contrast to others showing either no association,17, 26-28 or a negative association between 
sFlt-1 and fetal growth.16, 29-32 Asvold et al. 23 observed that low levels of sFlt-1 in early 
pregnancy were associated with an increased risk of SGA, which they postulate reflects low 
angiogenic activity overall during this period. We studied sFlt-1 levels somewhat later in 
pregnancy, at which time decreases in sFlt-1 may reflect a compensatory response to the 
already low VEGF. The dramatically lower median levels of VEGF-A among the SGA 
group that were visible even among women who were only 12-16 weeks gestation (Figure 
1a) may support this explanation.
MCP-1 is a chemokine that attracts and activates monocytes and macrophages to sites of 
inflammation. MCP-1/CCL2 has also been implicated in mediating angiogenesis in vitro and 
in vivo in a mouse model33, 34 and in the regulation of trophoblast invasion into the 
placental bed.35 Our finding that women with the highest MCP-1 levels had the lowest risk 
of a SGA birth is in accordance with a previous observation by Georgiou et al.36, that 
mothers of SGA infants had significantly lower concentrations of MCP-1 at 7-10 weeks of 
gestation. While we also observed lower median levels of MCP-1 overall among mothers of 
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SGA infants, our results contrastingly showed higher median MCP-1 levels among those 
whose specimens were tested between 12-16 weeks (Figure 1). Briana et al.37 found lower 
postnatal concentrations of MCP-1 among SGA infants and their mothers, though one 
cannot infer the temporality of the association from their study. Further research into MCP-1 
may help to clarify the role of this chemokine in the pathobiology of fetal growth restriction.
The adipocytokine hormone Leptin takes part in the regulation of energy balance, 
metabolism, the immune response, and T-cell activation. During pregnancy, Leptin is 
synthesized by the placenta and contributes to placental growth, nutrient transfer, 
angiogenesis, and trophoblast invasion.38 As reviewed by Briana et al., previous studies 
have reported contradictory findings related to Leptin and fetal growth restriction.38 Some 
studies have found associations between increased Leptin levels and IUGR. A proposed 
explanation for these findings is that Leptin secretion from trophoblast cells increases under 
hypoxic conditions,39 which can be characteristic of IUGR. Conversely, other studies have 
observed associations between reduced plasma Leptin levels and IUGR comparable to the 
results we we report here. These latter studies may indicate that under some circumstances, 
the placenta fails to increase Leptin secretion in response to reduced placental perfusion.38 
Collectively, these data suggest that some degree of leptin dysregulation has adverse 
consequences for fetal growth.
Strengths of this study include its prospective design, comprehensive assessment of 
angiogenic and inflammatory biomarkers, and ability to control for wide range of covariates 
as potential confounders. Although the examination of numerous biomarkers increases the 
potential for type I error through multiple testing, we maintained an alpha level of 0.05 for 
each test. Applying a Bonferroni correction to these results would have reduced the alpha 
level to 0.003 (0.05/18). The use of such a conservative alpha level would likely inflate the 
probability of type II error.40 As the goal of this discovery analysis was to identify 
biomarkers for further investigation in relation to SGA, we did not wish to dismiss any 
associations of interest. Furthermore, we selected biomarkers for inclusion in the study 
based on a priori hypotheses about their role in the pathogenesis of fetal growth restriction.
Our study may be limited by the use of SGA as the outcome, which is defined as being 
below the 10th percentile of birth weight for gestational age, since it is not entirely 
analogous to IUGR.41 The formal definition of IUGR refers to the failure of an infant to 
reach its genetic growth potential40 and is typically ascertained through ultrasound 
technology unavailable in this setting. Therefore, we may have misclassified some 
constitutionally small but healthy infants as SGA. Any misclassification of this sort would 
have occurred non-differentially and led to conservative relative risk estimates. In addition, 
some misclassification of LMP-based gestational ages may have occurred due to recall error, 
but any such errors would have also occurred independently of exposure status and likewise 
attenuated the results.
In summary, lower maternal levels of VEGF-A, PGF, MCP-1, and Leptin appear to precede 
SGA in this study cohort. Given the importance of each of these factors in placental vascular 
development, our findings support the hypothesis that alterations in levels of critical 
mediators of angiogenesis at mid-pregnancy contribute to the development of placental 
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vascular insufficiency, whereby the placenta cannot meet the metabolic demands of the 
growing fetus resulting in SGA outcomes. Although these findings are exploratory, they 
compel further investigation into the role of altered of angiogenesis in the pathobiology of 
SGA as well as the use of these markers as potential early diagnostic tools or targets for 
interventions to reduce SGA.
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Figure 1. Median levels of selected biomarkers according to gestational age at sample collection
a) VEGF-A, B) PGF, C) sFlt-1, D) MCP-1/CCL2, E) Leptin, F) sICAM-1
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Figure 2. Non-linear relation (p=0.001) between mid-pregnancy VEGF levels and (pg/ml) and 
SGA
Adjusted for literacy (yes/no), marital status (yes/no), gestational age at study entry (<20, 
20-25, 25-30 weeks), and district of recruitment (Ilala/Temeke/Kinondoni). Because VEGF 
levels were non-normally distributed, only those between the 5th and 95th percentile are 
displayed. The solid line shows the estimated odds ratio for mortality for each increasing 
pg/ml of VEGF compared to the reference value of 0.03. The horizontal line represents the 
null OR of 1.0. Dashed lines signify the upper and lower bounds of the 95% CI for the OR.
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Figure 3. Non-linear relation (p=0.008) between mid-pregnancy PGF levels and (pg/ml) and SGA
Adjusted for literacy (yes/no), marital status (yes/no), gestational age at study entry (<20, 
20-25, 25-30 weeks), and district of recruitment (Ilala/Temeke/Kinondoni). Because VEGF 
levels were non-normally distributed, only those between the 5th and 95th percentile are 
displayed. The solid line shows the estimated odds ratio for mortality for each increasing 
pg/ml of VEGF compared to the reference value of 74.07. The horizontal line represents the 
null OR of 1.0. Dashed lines signify the upper and lower bounds of the 95% CI for the OR.
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